Publication shows utility of GMO in solid tumor research with study on detection of complex genomic rearrangements in prostate cancer

Publication shows utility of GMO in solid tumor research with study on detection of complex genomic rearrangements in prostate cancer

Bionano Genomics

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study using optical genome mapping (OGM) to detect structural variants (SV ) and balanced rearrangements relevant to the pathogenesis of prostate cancer (PCa). GMOs identified VS in all samples, potentially improving the success rate of pathogenic variant screening and streamlining the detection process.

In the study published in international cancer cell, researchers analyzed ten consecutive PCa samples to study the ability of GMOs to detect genomic aberrations and complex SVs that may be associated with aggressive disease progression and resistance to androgen receptor-targeted therapies in solid tumor cancers. The PCa genome is characterized by frequently balanced rearrangements that affect several oncogenes and tumor suppressor genes. The study reported that the GMO helped identify alterations, deletions and translocations that may cause or contribute to genomic instability in cancer cells. The study authors highlighted the challenges associated with the use of traditional methods and cited the robust detection of cryptic rearrangements by GMOs with high resolution as evidence of its potential application as a first-line method in the analysis solid tumors.

“We have seen tremendous progress in the application of GMO in constitutional genetic disorders. In the context of oncology research, several previous publications have focused on the analysis of blood or bone marrow. This article is a good demonstration of the usefulness of GMOs for research on solid tumors. The study authors demonstrate that GMO may be more sensitive in detecting large structural variations and balanced rearrangements than traditional methods or whole genome sequencing. We believe this study provides a great example of how GMO can contribute to a sequencing-based approach for the molecular evaluation of solid tumors,” commented Erik Holmlin, PhD, President and CEO of Bionano. Genomics.

This publication is available here.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to find answers to complex questions in biology and medicine. The company’s mission is to transform the way the world views the genome through GMO solutions, diagnostic services and software. The company offers GMO solutions for applications in basic, translational and clinical research. Through its business Lineagen, Inc. d/b/a Bionano Laboratories, the company also provides diagnostic tests for patients with clinical presentations consistent with autism spectrum disorders and other neurodevelopmental disorders. Through its BioDiscovery business, the company also offers a leading-edge, platform-independent software solution that integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and a report of copy number variants, single nucleotide variants and absence of heterozygosity across the genome in a consolidated view. For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com Where www.biodiscovery.com

Bionano Genomics Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe”, “may”, “may”, “potential” and similar expressions (as well as other words or phrases that refer to future events, conditions or circumstances) convey uncertainty about future events or results and are intended to identify such forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyzes or current expectations regarding, among other things, GMO’s ability and utility to detect VS and balanced rearrangements relevant to the PCa pathogenesis; the ability and usefulness of GMO to detect cryptic rearrangements compared to traditional methods; the ability and utility of GMO to complement and facilitate sequence-based molecular assessment of solid tumors. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied by such forward-looking statements. Factors that could cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as the impact of the COVID-19 pandemic and the ongoing Ukrainian-Russian conflict and related sanctions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or enhancements to existing technologies; the failure of the GMO to achieve useful complementarity and facilitate sequence-based molecular assessment of solid tumors; failure of the GMO to detect SVs and balanced rearrangements relevant to PCa pathogenesis; failure of GMO to detect cryptic rearrangements compared to traditional methods; results of future studies contradicting the results reported in the publication referenced above; changes in our strategic and business plans; our ability to obtain sufficient financing to fund our strategic plans and marketing efforts; the ability of medical and research institutions to obtain funding to support the adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition generally, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on form 10-K for the year ended December 31, 2021 and in other filings subsequently filed by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date they are made and are based on management’s assumptions and estimates as of that date. We undertake no obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations:
Amy Conrad
tip of the juniper
+1 (858) 366-3243
amy@juniper-point.com

#Publication #shows #utility #GMO #solid #tumor #research #study #detection #complex #genomic #rearrangements #prostate #cancer

Leave a Comment

Your email address will not be published. Required fields are marked *